Alzheimer's: Disease Inights & Market Forecasts to 2024 - ResearchAndMarkets.com

DUBLIN--()--The "Alzheimer's: Disease Inights and Market Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.

Disease Indication Overview:

This section of the report gives the overview of Alzheimer's disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Alzheimer's disease. Further details on the profile of Alzheimer's patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report.

Drugs Overview and Attribute Analysis:

This part of the report highlights the importance of factors influencing the physician prescription decisions in Alzheimer's disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors. The report further details the drugs prescribed or expected to be prescribed in Alzheimer's disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the Alzheimer's market.

Drugs and Market Forecast to 2024:

The report in its last section provides sales and patient numbers forecast for the overall Alzheimer's market and drug wise forecasts from 2015 till 2024 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc.

Companies Mentioned

  • Chugai Pharmaceutical
  • Roche
  • AC Immune
  • Eli Lilly
  • PDL BioPharma
  • Bayer
  • TauRx Pharmaceuticals
  • Forest Laboratories
  • Daiichi Sankyo
  • Lundbeck
  • Allergan
  • Merz
  • Neurobiological Technologies
  • Hanmi Pharmaceutical
  • Adamas Pharmaceuticals
  • Wyeth
  • Eisai
  • Pfizer
  • Daewoong Pharmaceutical
  • Nitto Denko
  • Teikoku Seiyaku
  • Ono Pharmaceutical
  • Abbott Laboratories
  • BASF
  • Novartis
  • Esteve
  • LTS Gruppe
  • Shire
  • Takeda
  • Biogen
  • Neurimmune
  • MorphoSys
  • LifeArc

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 Disease Overview

4 Disease Epidemiology

5 Physian's Insights

6 Competitive Assessment and Attribute Analysis - Key Therapies

7 Pipeline Assessment

8 Market Outlook

9 Sales and Patient Forecast for Key Drugs

10 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/xsz2pn/alzheimers?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Alzheimer's Disease Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Alzheimer's Disease Drugs